Documente Academic
Documente Profesional
Documente Cultură
Presentation
Q2 2015
Risks
Serious complications may occur in any surgery, including da
Vinci Surgery, up to and including death. Individual surgical
results may vary. Patients should talk to their doctor to
decide if da Vinci Surgery is right for them. Patients and
doctors should review all available information on nonsurgical and surgical options in order to make an informed
decision. Please also refer to
http://www.daVinciSurgery.com/Safety for Important Safety
Information.
Contents Outline
Company Overview & Business
Model
Business Review
Corporate Overview
Founded in 1995, IPO 2000
Approximately 570,000 da Vinci procedures performed in
2014, up 9% from 2013
Q115 procedures up approximately 13%
$700-$3,200
per procedure
2014 Rev $1,070M
Annual Service
Agreement
da Vinci Surgical System
$0.6M - $2.5M
2014 Rev = $633M
$100K - $170K/Year
2014 Rev = $429M
da Vinci Si-e
$0.6M
$2.5M
2014: $1,880
Single-Site
$700
$3,200
2014: $140K
da Vinci Si-e
$100K
Typically Benign
Includes company estimates and approximate ranges
Dual Console Xi
Firefly
Endowrist
Vessel Sealer
Stapler
Dual Console Xi
$170K
Typically Cancer
Business Review
2014 Commentary
Areas of Strength
2014 Objectives
Drive adoption in General
Surgery
Launch key new products da
Vinci Xi
Increase organizational
capability in direct
international markets
Challenges
Stapler stop-use
US Gynecology macroenvironment
Single-Site Cholecystectomy
Q1 2015 Commentary
Areas of Strength
Procedure growth U.S. general surgery, U.S.
dVP macro trends, and international
Stapler
U.S.: Resumed shipping Si version and launched Xi version
Europe: Obtained CE Mark status for Si and Xi versions
600,000
2015 Guidance:
8-11% Growth
500,000
400,000
300,000
200,000
100,000
0
2009
2010
Urology
Company
Estimates
Company
estimates
2011
Gynecology
2012
2013
General Surgery
2014
Other
2015
90,000
80,000
70,000
60,000
50,000
40,000
30,000
20,000
10,000
0
2006
2007
2008
2009
Prostate
2010
Kidney
2011
2012*
Other
* U.S. Preventive Services Task Force Recommends Against PSA testing 5/2012
Company estimates
2013
2014
2010
Benign Hysterectomy
Company estimates
2011
2012
2013
Malignant Hysterectomy
2014
Other
2010
Upper GI / HPB
Company estimates
2011
2012
Lower GI / Colorectal
2013
Other
2014
International Performance
2014 Revenue - $641M,
up from $639M in 2013
30% of 2014 total revenue
Approximately 121,000
procedures performed in
2014, up 20% from 2013;
Q1 2015 up 22%
Strength in EU Systems
and Procedures
Strength in Asia
Procedures
Significant investments
supporting long term
growth
Japan: Transition to
direct sales structure,
clinical trials,
organizational growth
Europe: Sales
coverage, clinical data
and analysis
120,000
100,000
80,000
60,000
40,000
20,000
0
2009
2010
Europe
Company
Estimates
Company
estimates
2011
2012
Asia
Rest of World
2013
2014
da Vinci Xi
Designed for multi-quadrant
surgical access
Narrower arms with greater
reach
Lighter, slimmer endoscopes
that can move between ports
Computer assisted, streamlined
set up
Compatible surgical simulator
Why Xi Matters
Despite my obvious interest in minimally
invasive surgery I had resisted adopting previous
da Vinci platforms because of what I felt were
limitations. The da Vinci Xi platform is a game
changer for me. I now feel that this technology
will not just equal my standard laparoscopic
abilities but actually will allow me to reach new
levels in providing surgical care to my patients.
B. Harkins, MD, FACS General Surgeon, Texas
120
100
80
60
40
20
0
Q1
Q2
Q3
Q4
Q1
2013
Q2
Q3
2014
U.S.
Europe
Japan
Rest-of-World
Q4
Q1
2015
100%
90%
90%
80%
80%
70%
70%
60%
60%
50%
50%
40%
40%
30%
30%
20%
20%
10%
10%
0%
0%
Q114
Q214
S / Sie
Q314
Si
Q414
Xi
Q115
Q114
Q214
S / Sie
Q314
Si
Q414
Xi
Q115
Canada 25
556
Direct
Denmark 15
France 86
Norway 11
Germany 74 Czech Republic 7
UK 48
Austria 6
Belgium 33
Finland 5
Switzerland 27
Ireland 3
Sweden 24
Other 4
Netherlands 20
USA
2,254
Asia
Middle
East
35
Saudi Arabia 13
Brazil 15
Mexico 7
Argentina 5
Chile 5
Other 12
Latin
America
44
Distribution
Italy 81
Spain 30
Turkey 33
Russia 25
Greece 9
Romania 6
Other 9
365
Israel 7
Qatar 6
Other 9
South Africa 4
Intuitive sells directly to customers in the US, Korea, and the European countries indicated above. In
June 2014 direct sales rights were obtained in Japan. Sales are through distributor partners in all other
areas of the world including, Canada, Latin America, the Middle East, Asia and Australia.
Japan 194
South Korea 50
China 46
India 29
Taiwan 25
Singapore 7
Thailand 6
Other 8
Australia/New
Zealand 34
United States
International
2,500
2,000
1,500
1,000
500
0
Q110
Q111
Q112
Q113
Q114
Q115
Malignant
Hyst
Benign Hyst
Robotic
Source: ISI data as well as estimates
Other MIS
Open
Malignant
Hyst
Benign Hyst
Robotic
Source: ISI data as well as estimates
Colorectal
Other MIS
Open
Ventral
Hernia
Thoracic
Malignant
Hyst
Other MIS
Colorectal
Robotic
Gastrectomy
Open
Source: ISI data as well as estimates. OUS defined as Western Europe, Canada, Australia, South Korea and Japan
Thoracic
Populations Matter
(e.g., Rectal Resection)
Market Share %
Open Surgery
da Vinci LAR
Laparoscopy
}
}
Patient Perspective
Open vs MIS
MIS Surgeon Perspective
dV vs Lap
Product Milestones
Continue da Vinci Xi Product
Launch:
Integration of da Vinci Sp
Current Xi Configuration
Integration of da Vinci Sp
Xi with Sp Patient Cart and Instruments
Corporate Assets
Extraordinary people
2015 Priorities
Drive adoption of colorectal surgery and hernia
repair
Complete da Vinci Xi launch additional products
and international markets; reduce product costs
Develop market and organizational capabilities in EU
and Asia
Initiate customer learning on da Vinci Sp